Smooth Muscle Actin (SMA)

Overview

The Smooth Muscle Actin (SMA), also known as Alpha-Smooth Muscle Actin (α-SMA), is an isoform of the actin protein and a highly sensitive marker for myoepithelial differentiation. Although not specific, any cell with substantial actin expression can test positive for SMA. It is a cytoskeletal protein with a molecular weight of approximately 42,000 kDa, found in almost all cells.

Structurally, SMA exists in two forms: globular actin (G-actin), which polymerizes into filamentous actin (F-actin). F-actin filaments form double-stranded helical structures that play a critical role in muscle contraction, maintaining cytoskeletal integrity, and facilitating cellular motility.

Physiologically, SMA is essential for blood vessel constriction, gastrointestinal motility, airway contraction, milk ejection, tissue repair, and scar formation. It is widely used as an immunohistochemistry (IHC) marker in identifying cells of myoepithelial origin, smooth muscle tumors, and salivary gland tumors, making it clinically significant in both diagnostics and prognosis.

Symptoms

While SMA itself is not a disease, its expression patterns provide valuable diagnostic and prognostic insights into various medical conditions. Abnormal expression or detection of SMA in tissues can be associated with:

1. Tumor formation – SMA positivity is common in tumors like leiomyoma, leiomyosarcoma, fibromatosis, gastrointestinal stromal tumors (GISTs), glomus tumors, and myofibroblastic sarcomas.
2. Salivary gland tumors – SMA is a gold-standard marker for tumors of myoepithelial origin, including adenoid cystic carcinoma and myoepithelioma.
3. Basal cell carcinoma – SMA immunoexpression may signal aggressive tumor behavior in cutaneous forms.
4. Pulmonary fibrosis – SMA positivity in myofibroblasts is a potential prognostic factor in idiopathic pulmonary fibrosis.
5. Liposarcoma differentiation – Myogenic differentiation (SMA or SMA + desmin) is linked to poorer 5-year disease-free survival rates.

Thus, the “symptoms” linked to SMA are reflected in the diseases where it is used as a biomarker rather than patient-reported clinical symptoms.

Causes

Abnormal SMA expression or positivity in tissue samples is primarily caused by:

1. Myoepithelial and smooth muscle origin tumors – such as leiomyoma, leiomyosarcoma, glomus tumor, perineurioma, synovial sarcoma, and rhabdomyosarcoma.
2. Reactive processes – like tissue injury and repair, where myofibroblasts express SMA during extracellular matrix remodeling and scar formation.
3. Fibroblastic and stromal tumors – including endometrial stromal sarcoma, fibromatosis, cellular angiofibroma, and desmoplastic melanoma.
4. Infectious and viral associations – certain conditions, such as EBV-associated smooth muscle tumors (EBV SMT) may also display SMA positivity.

The causes reflect the pathological conditions where SMA is expressed and detected, making it an indispensable immunohistochemical marker.

Risk Factors

The relevance of SMA testing increases in patients with risk factors for tumors or conditions where SMA plays a diagnostic or prognostic role. These include:

1. Patients with suspected smooth muscle tumors – gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas.
2. Individuals with salivary gland tumors, where SMA is the gold-standard marker for diagnosis.
3. Cancer patients under evaluation for tumor type and aggressiveness – especially basal cell carcinoma, liposarcoma, and mesothelioma.
4. Patients with pulmonary fibrosis, where SMA can help assess disease progression.
5. Individuals with viral or immune-related tumors, such as EBV-associated smooth muscle tumors.

Recognizing these risk groups ensures early application of SMA immunostaining for accurate and timely diagnosis.

Prevention

Since SMA is a protein marker and not a condition itself, there are no direct preventive measures to alter its expression. However, preventive strategies can be applied indirectly by addressing underlying risks and ensuring timely diagnosis:

1. Early detection of tumors – Routine check-ups and biopsy evaluations can help identify abnormal SMA expression in tumor tissues.
2. Regular monitoring in high-risk patients – Individuals with chronic pulmonary diseases or known predisposition to sarcomas should undergo periodic evaluation.
3. Pathological confirmation – Using SMA immunohistochemistry in suspected tumors ensures accurate diagnosis and prevents misclassification.
4. Comprehensive testing – SMA testing should be complemented with other markers, such as desmin, for better diagnostic accuracy and prognosis assessment.